Meeting
2020 ASCO Virtual Scientific Program
Registrational dataset from the phase I/II ARROW trial of pralsetinib (BLU-667) in patients (pts) with advanced RET fusion+ non-small cell lung cancer (NSCLC).
Presenter
Justin F. Gainor, MD
Massachusetts General Hospital
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Videos & Slides Details
Session Type
Poster Discussion Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Clinical Trial Registration Number
NCT03037385
Citation
J Clin Oncol 38: 2020 (suppl; abstr 9515)
DOI
10.1200/JCO.2020.38.15_suppl.9515
Abstract #
9515
Poster Bd #
281
Abstract Disclosures
Similar Videos & Slides
Videos & Slides
2021 ASCO Annual Meeting
Safety and efficacy of pralsetinib in patients with advanced RET fusion-positive non-small cell lung cancer: Update from the ARROW trial.
Speaker: Giuseppe Curigliano, MD, PhD
Videos & Slides
2022 ASCO Annual Meeting
Pralsetinib in patients (pts) with advanced or metastatic RET-altered thyroid cancer (TC): Updated data from the ARROW trial.
Speaker: Aaron Scott Mansfield, MD
Videos & Slides
2021 ASCO Annual Meeting
Clinical activity and safety of the RET inhibitor pralsetinib in patients with RET fusion-positive solid tumors: Update from the ARROW trial.
Speaker: Vivek Subbiah, MD
Videos & Slides
2019 ASCO Annual Meeting
Clinical activity and tolerability of BLU-667, a highly potent and selective RET inhibitor, in patients (pts) with advanced RET-fusion+ non-small cell lung cancer (NSCLC).
Speaker: Justin F. Gainor, MD